Bio-Rad Laboratories BIO Finance Lease Liabilities
Finance Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.
The official record: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Rad Laboratories's finance lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Rad Laboratories's finance lease liabilities?
- Bio-Rad Laboratories (BIO) reported finance lease liabilities of $8.6M in Q1 2026.
- How has Bio-Rad Laboratories's finance lease liabilities changed year-over-year?
- Bio-Rad Laboratories's finance lease liabilities decreased by 4.4% year-over-year, from $9M to $8.6M.
- What is the long-term trend for Bio-Rad Laboratories's finance lease liabilities?
- Over 5 years (2020 to 2025), Bio-Rad Laboratories's finance lease liabilities has grown at a -4.6% compound annual growth rate (CAGR), from $11M to $8.7M.
- What does finance lease liabilities mean?
- The long-term debt-like obligations resulting from leasing assets that the company effectively controls.
- How do you interpret finance lease liabilities?
- An increase reflects a strategy of financing capital equipment through long-term lease arrangements rather than cash purchases or traditional debt.
- How does finance lease liabilities compare across companies?
- Common in life sciences and diagnostics firms that lease high-value manufacturing or research equipment.